Literature DB >> 2745205

Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications.

K M Greven1, W J Curran, R Whittington, J Fanning, M E Randall, J Wilder, A J Peters.   

Abstract

The poor outcome of certain patients with Stage III endometrial carcinoma has led some investigators to direct adjuvant therapy to the abdominal cavity. To better define failure patterns, a review of 126 patients with Stage III endometrial carcinoma treated at four institutions was performed. Seventy-four patients were diagnosed at surgery with pathologic Stage III disease, whereas 52 patients presented with clinical Stage III disease. Most patients received external beam irradiation to the pelvis with a variety of boost techniques. Site of disease, grade, depth of invasion, and pathology were examined for prognostic significance. Actuarial techniques were used to analyze survival and recurrences. For the 52 clinical Stage III patients, 5-year survival was 36%. The median survival of 20 patients who were treated with radiation therapy (RT) following biopsy was 9 months. Pelvic control was poor in these patients, with 16/18 evaluable patients failing locally. Thirty-two patients who underwent resection with adjunctive RT had a 5-year survival of 48%. Local failure occurred in 40% of patients, whereas 38% of patients had abdominal failure. Isolated abdominal failure was infrequent with 6% failing as isolated recurrence, and 16% failing as the only site of distant disease. For 74 pathologic Stage III patients, 5-year survival was 54%. Local failure resulted in 20% of patients, and isolated abdominal failure occurred in 7% of patients. The subset of patients with ovarian or tubal involvement included 42 patients, with a 5-year survival of 60%. Further analysis of this subset by grade and depth of myometrial penetration was found to be prognostically significant. Twenty-four patients who were Stage III because of parametrial or pelvic peritoneal involvement had a 5-year survival of 44%. Local control and survival is improved in Stage III patients treated with surgical resection. The high rate of distant metastases in both abdominal and extra-abdominal sites has significant therapeutic implications.

Entities:  

Mesh:

Year:  1989        PMID: 2745205     DOI: 10.1016/0360-3016(89)90367-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Combined chemotherapy and radiation improves survival for node-positive endometrial cancer.

Authors:  Larissa J Lee; Akila N Viswanathan
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

2.  Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.

Authors:  Melissa Rasar Young; Susan A Higgins; Elena Ratner; James B Yu; Sheida Mani; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Shari Damast
Journal:  Int J Gynecol Cancer       Date:  2015-03       Impact factor: 3.437

3.  Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a review of 67 patients.

Authors:  Salih Taşkın; Fırat Ortaç; Korhan Kahraman; Göksu Göç; Derya Oztuna; Mete Güngör
Journal:  Int J Clin Oncol       Date:  2011-11-18       Impact factor: 3.402

4.  Helical tomotherapy provides efficacy similar to that of intensity-modulated radiation therapy with dosimetric benefits for endometrial carcinoma.

Authors:  Chen-Hsi Hsieh; Pei-Wei Shueng; Sheng-Mou Hsiao; Ming-Chow Wei; Wen-Yih Wu; Hsu-Dong Sun; Hui-Ju Tien; Li-Ying Wang; Yen-Ping Hsieh
Journal:  Onco Targets Ther       Date:  2012-10-01       Impact factor: 4.147

Review 5.  Adjuvant chemo-radiotherapy in the "sandwich" method for high risk endometrial cancer--a review of literature.

Authors:  Yachun Bie; Zhenyu Zhang; Xiaolan Wang
Journal:  BMC Womens Health       Date:  2015-06-24       Impact factor: 2.809

Review 6.  Adjuvant therapy for endometrial cancer.

Authors:  Maria C Deleon; Natraj R Ammakkanavar; Daniela Matei
Journal:  J Gynecol Oncol       Date:  2014-04-09       Impact factor: 4.401

7.  α-bisabolol enhances radiotherapy-induced apoptosis in endometrial cancer cells by reducing the effect of XIAP on inhibiting caspase-3.

Authors:  Dongmei Fang; Hongxin Wang; Min Li; Wenwen Wei
Journal:  Biosci Rep       Date:  2019-06-10       Impact factor: 3.976

8.  Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Authors:  David S Miller; Virginia L Filiaci; Robert S Mannel; David E Cohn; Takashi Matsumoto; Krishnansu S Tewari; Paul DiSilvestro; Michael L Pearl; Peter A Argenta; Matthew A Powell; Susan L Zweizig; David P Warshal; Parviz Hanjani; Michael E Carney; Helen Huang; David Cella; Richard Zaino; Gini F Fleming
Journal:  J Clin Oncol       Date:  2020-09-29       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.